The tweet was deleted by the author.
But we saved everything 🙂.
MeiraGTx continues to make strides in medical innovation with its latest gene therapy for Parkinson's disease. The therapy, which involves a one-time brain injection, is being hailed as a potential game changer for its ability to restore movement and slow disease progression.
The therapy has recently received the Regenerative Medicine Advanced Therapy (RMAT) status, paving the way for a global clinical trial. This status, granted by the U.S. Food and Drug Administration, is a significant milestone that facilitates faster development and review processes. MeiraGTx's announcement underscores the company's commitment to advancing treatment options for neurological disorders.